Alkermes plc (ALKS)
ALKS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1520262/000119312526068925/0001193125-26-068925-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ALKS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Ireland |
| IPO year | 1991 |
| SEC CIK | 0001520262 |
| SEC industry code | Pharmaceutical Preparations |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $1.5B |
| Net income | $241.7M |
| Operating income | $254.0M |
| Net margin | 16.4% |
| Operating margin | 17.2% |
| Revenue growth | -5.2% |
| Cash | $388.6M |
| Total assets | $2.5B |
| P/E (computed) | 32.4× |
| P/S (computed) | 5.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-03 |
| Cash and burn | $631.3M cash; operating cash flow $60.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 168,043,540 (2026-10-30); 165,117,509 a year earlier; 166,881,286 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $10.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $480.1M | $16.3M | $93.5M | $631.3M | $1.5B | $1.8B | 10-Q 2026-11-03 |
| Q2 2026 2026-06-30 | $496.0M | $501K | $145.2M | $511.5M | $1.5B | $1.7B | 10-Q 2026-07-28 |
| Q1 2026 2026-03-31 | $392.9M | -$66.5M | -$165.7M | $351.6M | $1.5B | $1.6B | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | $384.5M | $49.3M | $170.1M | $388.6M | $0 | $1.5B | 10-K 2026-02-25 |
| Q3 2025 2025-09-30 | $394.2M | $82.8M | $101.7M | $616.4M | No debt tags | $1.5B | 10-Q 2026-11-03 |
| Q2 2025 2025-06-30 | $390.7M | $87.1M | $150.2M | $521.2M | No debt tags | $1.5B | 10-Q 2026-07-28 |
| Q1 2025 2025-03-31 | $306.5M | $22.5M | $98.8M | $399.8M | No debt tags | $1.5B | 10-Q 2026-05-05 |
| Q4 2024 2024-12-31 | $430.0M | $146.5M | $190.4M | $291.1M | No debt tags | $1.6B | 10-K 2026-02-25 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report | 10-K | 2026-02-25 |
| Latest quarterly / interim | 10-Q | 2026-11-03 |
| Latest current report | 8-K | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-05-13 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.5% |
| 1 month | +18.4% |
| 3 months | -4.9% |
| Year to date | +68.1% |
| 1 year | +51.7% |
| From 52-week high | -14.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CORT | Corcept Therapeutics Incorporated | $69.22 | -5.10% | $7.6B |
| PTGX | Protagonist Therapeutics Inc. | $124.83 | -4.67% | $8.1B |
| RYTM | Rhythm Pharmaceuticals Inc. | $107.48 | -6.56% | $7.5B |
| CYTK | Cytokinetics Incorporated | $53.17 | -5.27% | $7.4B |
| KNSA | Kiniksa Pharmaceuticals International plc | $94.23 | -2.18% | $7.4B |
| AMRX | Amneal Pharmaceuticals Inc. | $21.23 | -0.70% | $7.4B |
| ABVX | Abivax SA | $83.61 | -4.53% | $7.3B |
| AXSM | Axsome Therapeutics Inc. | $137.01 | -3.30% | $7.2B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier